CD274 and cervical cancer: A phase II study of atezolizumab in combination with the vascular endothelial growth factor (VEGF) inhibitor bevacizumab in patients with advanced cc indicated that the addition of bevacizumab to PD-L1 blockade did not appear to increase the ORR (0%) in cervical cancer.